News & Updates

A single intranasal dose of the psychedelic mebufotenin benzoate helps improve symptoms in adults with treatment-resistant depression, with the benefit emerging as early as day 1 after dosing and persisting for 8 weeks, according to a phase IIb trial said to be the largest clinical evaluation to date of mebufotenin administered as a nose spray.

Treatment with antibiotics appears to increase the risk of irritable bowel syndrome (IBS) development, particularly following a gastrointestinal (GI) infection, suggests a study.

Treatment with risankizumab results in fast and sustained favourable clinical, endoscopic, and radiologic outcomes in patients with Crohn’s disease (CD), a real-world study has shown.

Use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) among adults with weight regain after metabolic and bariatric surgery (MBS) results in greater weight loss without compromising safety, according to a study.

Tirzepatide and injectable semaglutide deliver similar effectiveness against liver disease progression and major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes (T2D), a study has shown.

In the real-world treatment of patients with inflammatory bowel disease (IBD), the use of guselkumab yields high remission rates and has an overall safety profile that mirrors those in randomized controlled trials, according to a large prospective study.

In the treatment of Chinese patients with metabolic dysfunction-associated steatohepatitis (MASH) and F2 or F3 fibrosis, the use of the selective thyroid hormone receptor-β agonist simedeutirom helps improve disease activity without worsening of fibrosis, as shown in a phase IIb trial.